Zyversa Therapeutics, Inc. (ZVSA) — 8-K Filings

8-K Filings (19)

• ZyVersa Therapeutics Reports Officer/Director Changes — Dec 3, 2025 Risk: medium
  ZyVersa Therapeutics, Inc. filed an 8-K on December 3, 2025, reporting on the departure of directors or certain officers, the election of directors, and the app
• ZyVersa Therapeutics Announces Board and Executive Changes — Oct 15, 2025 Risk: medium
  ZyVersa Therapeutics, Inc. announced on October 10, 2025, changes in its board of directors and executive compensation arrangements. The filing details the depa
• ZyVersa Therapeutics Faces Delisting Concerns — Sep 18, 2025 Risk: high
  ZyVersa Therapeutics, Inc. filed an 8-K on September 18, 2025, reporting a notice of delisting or failure to meet continued listing standards. The company was f
• ZyVersa Therapeutics Files 8-K — Jul 28, 2025 Risk: low
  ZyVersa Therapeutics, Inc. filed an 8-K on July 28, 2025, reporting other events and financial statements as of July 25, 2025. The company, formerly Larkspur He
• ZyVersa Therapeutics Faces Delisting Notice — Jul 16, 2025 Risk: high
  ZyVersa Therapeutics, Inc. filed an 8-K on July 15, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerly
• ZyVersa Therapeutics Files 8-K with Material Agreement — Jul 9, 2025 Risk: medium
  On July 8, 2025, ZyVersa Therapeutics, Inc. entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity securities a
• ZyVersa Therapeutics Files 8-K: Material Agreement & Equity Sales — Jun 25, 2025 Risk: medium
  ZyVersa Therapeutics, Inc. announced on June 24, 2025, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales of
• ZyVersa Therapeutics Files 8-K on Board Changes and Shareholder Votes — Jun 12, 2025 Risk: medium
  ZyVersa Therapeutics, Inc. filed an 8-K on June 12, 2025, reporting on the departure of directors, election of new directors, and compensatory arrangements. The
• ZyVersa Therapeutics Faces Delisting Concerns — May 30, 2025 Risk: high
  ZyVersa Therapeutics, Inc. filed an 8-K on May 30, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerly L
• ZyVersa Therapeutics Changes Certifying Accountant — Apr 7, 2025 Risk: medium
  ZyVersa Therapeutics, Inc. filed an 8-K on April 7, 2025, reporting changes in its certifying accountant. The filing indicates a change in the company's indepen
• ZyVersa Therapeutics Reports Material Agreements & Equity Sales — Mar 7, 2025 Risk: medium
  ZyVersa Therapeutics, Inc. filed an 8-K on March 7, 2025, reporting several key events that occurred on March 4, 2025. These include entering into a material de
• ZyVersa Therapeutics Files 8-K: Material Agreement & Equity Sales — Nov 6, 2024 Risk: medium
  ZyVersa Therapeutics, Inc. announced on November 5, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales
• ZyVersa Therapeutics Announces Director Changes and Officer Appointments — Oct 30, 2024 Risk: medium
  ZyVersa Therapeutics, Inc. filed an 8-K on October 30, 2024, reporting on the departure of a director, the election of new directors, and the appointment of new
• ZyVersa Therapeutics Enters Material Definitive Agreement — Sep 16, 2024 Risk: medium
  ZyVersa Therapeutics, Inc. announced on September 16, 2024, that it entered into a Material Definitive Agreement. The company, formerly known as Larkspur Health
• ZyVersa Therapeutics Files 8-K with Material Agreement — Aug 1, 2024 Risk: medium
  ZyVersa Therapeutics, Inc. announced on August 1, 2024, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales of
• ZyVersa Therapeutics Files 8-K on Security Holder Rights — Apr 25, 2024 Risk: medium
  ZyVersa Therapeutics, Inc. filed an 8-K on April 25, 2024, reporting material modifications to the rights of security holders and amendments to its articles of
• ZyVersa Therapeutics Files 8-K on Shareholder Votes & Reg FD — Apr 17, 2024 Risk: low
  ZyVersa Therapeutics, Inc. filed an 8-K on April 17, 2024, to report on matters submitted to a vote of security holders and Regulation FD disclosures. The compa
• ZyVersa Therapeutics Faces Nasdaq Delisting Warning — Mar 8, 2024 Risk: high
  ZyVersa Therapeutics, Inc. announced on March 6, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. The
• ZyVersa Therapeutics Faces Delisting Concerns — Mar 1, 2024 Risk: high
  ZyVersa Therapeutics, Inc. filed an 8-K on March 1, 2024, to report a notice of delisting or failure to meet continued listing standards. The company was former

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX